- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Invictus MD Closes $16,218,065 Bought Deal Private Placement
Invictus MD Strategies Corp (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that it has closed its previously announced bought deal private placement (the “Offering”), with Canaccord Genuity Corp. and Eventus Capital Corp. (collectively, the “Underwriters”), including a portion of the over-allotment option, for aggregate gross proceeds of $16,218,065. A total of 9,829,130 units (the “Units”), including those pursuant to the exercise of the over-allotment option, were issued at a price of $1.65 per Unit.
Invictus MD Strategies Corp (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that it has closed its previously announced bought deal private placement (the “Offering”), with Canaccord Genuity Corp. and Eventus Capital Corp. (collectively, the “Underwriters”), including a portion of the over-allotment option, for aggregate gross proceeds of $16,218,065. A total of 9,829,130 units (the “Units”), including those pursuant to the exercise of the over-allotment option, were issued at a price of $1.65 per Unit.
Each Unit is comprised of one common share and one half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share (a “Warrant Share”) until September 2, 2018 at an exercise price of $2.35 per Warrant Share. The Warrants are subject to an acceleration provision that allows the Company to give notice of an earlier expiry date if the Company’s daily volume weighted average share price on the Canadian Securities Exchange (or such other stock exchange the Company may be trading on) is greater than $3.75 for 10 consecutive trading days .
Net proceeds from the Offering will be used for expansion plans for the Company’s assets and for general working capital purposes. As compensation, the Underwriters received a commission of 7% of the gross proceeds raised which was paid partly in cash and partly through the issuance of 281,818 Units having the same terms as the Units issued to purchasers. The Company also issued to the Underwriters a total of 688,039 Underwriters’ warrants. Each Underwriters’ warrant is exercisable to acquire one common share at a price of $1.65 until September 2, 2018 .
All securities issued or issuable under the Offering are subject to a four-month hold period expiring on July 3, 2017.
About Invictus MD Strategies Corp.
Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.
Click here to connect with Invictus MD Strategies Corp (CSE: IMH; OTC: IVITF; FRA: 8IS).
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.